Abstract
Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Current Pharmaceutical Design
Title:Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Volume: 24 Issue: 23
Author(s): H. Susana Marinho, Paulo Marcelino, Helena Soares and Maria Luísa Corvo*
Affiliation:
- Instituto de Investigacao do Medicamento (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa,Portugal
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Abstract: Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Export Options
About this article
Cite this article as:
Marinho Susana H. , Marcelino Paulo , Soares Helena and Corvo Luísa Maria*, Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807124356
DOI https://dx.doi.org/10.2174/1381612824666180807124356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prophylactic Neuroprotection
Current Drug Targets Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Adult Stem Cell Therapy for Acute Brain Injury in Children
CNS & Neurological Disorders - Drug Targets Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews The Design of Competitive, Small-molecule Inhibitors of Coagulation Factor Xa
Current Topics in Medicinal Chemistry Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Nitric Oxide Modulation as a Potential Molecular Mechanism Underlying the Protective Role of NaHS in Liver Ischemia Reperfusion Injury
Current Molecular Pharmacology Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System
Current Drug Metabolism Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Emerging Anticoagulants
Current Medicinal Chemistry